66 related articles for article (PubMed ID: 1637256)
1. Post-marketing surveillance of probucol (Sinlestal) in Japan.
Kosasayama A; Yoshida M; Okada S
Artery; 1992; 19(3):147-61. PubMed ID: 1637256
[TBL] [Abstract][Full Text] [Related]
2. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
[TBL] [Abstract][Full Text] [Related]
3. Clinical investigation on the hypolipidemic effect of simvastatin versus probucol in hemodialysis patients.
Fiorini F; Patrone E; Castelluccio A
Clin Ter; 1994 Sep; 145(9):213-7. PubMed ID: 7813167
[TBL] [Abstract][Full Text] [Related]
4. [Pravastatin vs. probucol in the treatment of hypercholesterolemia. A double-blind study].
Sienra-Pérez JC; Lerman-Garber I; Ahumada-Ayala M; Castañón-Romo C; Cardoso-Saldaña G; Laguna-Castellanos M; Posadas-Romero C
Arch Inst Cardiol Mex; 1991; 61(4):365-73. PubMed ID: 1953212
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of acipimox and pravastatin in patients with combined hyperlipidemia.
Fogari R; Marasi G; Vanasia A; Zoppi A; Lusardi P; Preti P
Int J Clin Pharmacol Ther; 1997 Feb; 35(2):61-4. PubMed ID: 9147709
[TBL] [Abstract][Full Text] [Related]
6. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
7. [Effect of long-term cardiac training on lipids concentration in patients with chronic heart ischemic disease treated with simvastatin].
Kałka D; Sobieszczańska M; Kopka L; Marciniak W; Zawadzka-Bartczak E; Bak A; Popielewicz-Kautz A; Korzeniowska J; Janczak J; Adamus J
Pol Merkur Lekarski; 2007 Feb; 22(128):101-6. PubMed ID: 17598652
[TBL] [Abstract][Full Text] [Related]
8. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial.
McCrindle BW; Ose L; Marais AD
J Pediatr; 2003 Jul; 143(1):74-80. PubMed ID: 12915827
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of 12-week treatment with fenofibrate 300 mg in Thai dyslipidemic patients.
Koanantakul B; Jeamanukulkit N; Piamsomboon C; Chawantanpipat C; Khanacharoen I
J Med Assoc Thai; 2004 Nov; 87(11):1281-5. PubMed ID: 15825700
[TBL] [Abstract][Full Text] [Related]
11. [Effects of medium-term probucol treatment on plasma lipids and lipoproteins. 16 cases of type IIa and IIb hyperlipoproteinaemia (author's transl)].
Rouffy J; Chanu B; Bakir R; Goy-Loepper J; Saya C
Nouv Presse Med; 1980 Oct; 9(40):3014-7. PubMed ID: 7443443
[TBL] [Abstract][Full Text] [Related]
12. Effects of ethyl-2-(4-chlorophenyl)-5-ethoxy-4-oxazole acetate (Y-9738) on the serum lipids of patients with hyperlipidemia and/or hypo-HDL-emia.
Kajiyama G; Maruhashi A; Yamada K; Kawamoto T; Nakao S; Kubota S; Tsunoda Y
Arzneimittelforschung; 1984; 34(6):730-3. PubMed ID: 6541494
[TBL] [Abstract][Full Text] [Related]
13. Effect of probucol on triton induced hyperlipidemias in CFY rats.
Krishnamurthy A; Thapar GS; Shridhar DR
Artery; 1985; 13(2):87-94. PubMed ID: 4084069
[TBL] [Abstract][Full Text] [Related]
14. [Clinical research on the hypolipidemic action of a probucol preparation].
Naumova R; Kerekovska M; Goranov I; Balabanski L
Vutr Boles; 1986; 25(2):73-7. PubMed ID: 3716382
[TBL] [Abstract][Full Text] [Related]
15. The effect of pirozadil on plasma lipids and lipoproteins in 1185 hyperlipidaemic subjects. Multicentre study in general practice in Spain.
Tapounet R; Marti Ragué I
Drugs Exp Clin Res; 1987; 13(7):447-50. PubMed ID: 3652931
[TBL] [Abstract][Full Text] [Related]
16. Impact of fluvastatin on hyperlipidemia after renal transplantation.
Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
[TBL] [Abstract][Full Text] [Related]
17. Gemfibrozil in hyperlipidaemia: an open, single blind trial.
Varthakavi PK; Turakhia DP; Sharma SS; Salgaonkar DS; Nihalani KD; Joshi VR
J Assoc Physicians India; 1990 Feb; 38(2):136-40. PubMed ID: 2380132
[TBL] [Abstract][Full Text] [Related]
18. [Effect of probucol on cardiac electrophysiology in anginal patients with hyperlipidemia and diabetes mellitus type II].
Anikin VV; Savin VV; Lupanov VP; Razygraev RA
Ter Arkh; 2000; 72(8):28-30. PubMed ID: 11019422
[TBL] [Abstract][Full Text] [Related]
19. [Acipimox (Olbetam) as a secondary hypolipemic agent in combined hypertriglyceridemia and hyperlipidemia].
Yeshurun D; Hamood H; Morad N; Naschitz J
Harefuah; 2000 Apr; 138(8):650-3, 710. PubMed ID: 10883206
[TBL] [Abstract][Full Text] [Related]
20. Factors predictive of marked decrease in HDL-C by probucol treatment.
Yashiro A; Nakashima Y; Segawa J; Kawashima T; Kuroiwa A
Artery; 1990; 18(1):16-31. PubMed ID: 2085284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
